Delivery Order SPE2DB22D2007-SPE2DB25FJ4RR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,547.13 to AmerisourceBergen Drug Corp for MYFEMBREE 40 MG-1 MG-0.5 MG tablets (28-count), a pharmaceutical product to be delivered to the company's facility in Conshohocken, Pennsylvania. This firm fixed-price delivery order, issued on June 2, 2025, with an ultimate completion date of June 3, 2025, represents a non-competitive award under an existing contract vehicle. The award reflects routine pharmaceutical supply procurement...
- The Defense Logistics Agency awarded a $2,233.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE 40 MG-1 MG-0.5 MG tablets (28-count) with an ultimate completion date of June 2, 2025. This non-set-aside award was made competitively and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $8,499.46 to AmerisourceBergen Drug Corp for the supply of Myfembree (40 mg, 1 mg, 0.5 mg tablets, 28-count package) on April 25, 2025, with an ultimate completion date of April 28, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical delivery...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,547.13, is for the delivery of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, a pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of April 8, 2025. There is no set-aside designation for this contract. AmerisourceBergen Drug Corp holds a...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $7,002.97, is a delivery order with a firm fixed price. It covers the provision of MYFEMBREE 40 MG-1 MG-0.5 MG tablets, with an ultimate completion date of November 8, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The Defense Logistics Agency Troop Support Medical awarded a $1,530.93 delivery order to Amerisourcebergen Drug Corporation for the product "MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S." The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is September 5-6, 2023. This firm fixed price order was placed under an indefinite-delivery/indefinite-quantity contract vehicle, though details of the underlying contract were not...
- This federal contract award, valued at $1,557.13, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S pharmaceutical products. The contract, which runs until January 8, 2025, is a firm fixed price delivery order with no set-aside designation, indicating open competition. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, holds a significant Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Myfembree (40 mg, 1 mg, and 0.5 mg tablets) in a quantity of 28 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $2,149.77 and is scheduled for completion by September 9, 2025. The contract represents a non-set-aside procurement, indicating AmerisourceBergen's competitive selection among qualified vendors....
- The Defense Logistics Agency awarded a $3,364.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for pharmaceutical products on August 22, 2025, with an ultimate completion date of August 25, 2025. The delivery order covers Myfembree 40 mg–1 mg–0.5 mg tablets in a 28-day supply, a hormonal contraceptive medication. This is a non-set-aside competitive award issued against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The U.S. Defense Logistics Agency (DLA) awarded a $3,217.50 Firm Fixed Price Delivery Order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S medication. The contract has an ultimate completion date of May 20, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4RRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,156.39 to AmerisourceBergen Drug Corp for MYFEMBREE pharmaceutical products in tablet form (40 mg, 1 mg, and 0.5 mg strengths, 28-count package) with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location and serve as the prime contractor for this federal medical supply delivery. This delivery order represents a small-value transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC provides comprehensive pharmaceutical and medical supply support for military healthcare programs globally, encompassing specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. AmerisourceBergen Drug Corp's significant federal contract portfolio with the DLA demonstrates its established capacity to meet military and veteran healthcare procurement requirements through competitive federal contracting processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 9/5/25 |